What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

@inproceedings{Kallenberg2011WhatHW,
  title={What have we learned from clinical trials in primary Sj{\"o}gren's syndrome about pathogenesis?},
  author={Cees G. M. Kallenberg and A Vissink and Frans G. M. Kroese and Wayel H. Abdulahad and Hendrika Bootsma},
  booktitle={Arthritis research & therapy},
  year={2011}
}
In vitro and in vivo experimental data have pointed to new immunopathogenic mechanisms in primary Sjögren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. This has taught us that the role of proinflammatory cytokines, in particular TNFα, is not crucial in the immunopathogenesis of pSS. B cells appear to play a major role, as depletion of B cells leads to restoration of salivary flow and is… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Similar Papers

Loading similar papers…